JP Morgan (NYSE: JPM) Cuts General Mills (NYSE: GIS) Price Target to $31

JP Morgan lowered its price target on General Mills to $31, maintaining an Underweight rating on the packaged food company Thursday, June 4. The downgrade reflects analyst concerns about emerging health trends and GLP-1 drug adoption pressuring growth outlooks across the food sector.

The action follows a broader Bernstein note flagging that GLP-1 medications (diabetes and weight-loss drugs) and evolving health trends threaten growth trajectories for major food manufacturers. General Mills is divesting Haagen-Dazs shops in China as part of its portfolio optimization, the company disclosed separately.

By the Numbers

• JP Morgan price target: $31
• General Mills stock traded at $32.87, up 2.18% on Thursday, June 4
• Trailing P/E: 8.0x; forward P/E: 10.3x (TTM — may not reflect latest quarter)
• Revenue growth (TTM): 2.2%
• Earnings growth (TTM): -14.5%

Why It Matters

The downgrade underscores a structural headwind for packaged food companies: rising GLP-1 adoption may shift consumer demand away from calorie-dense packaged foods toward lower-consumption patterns or fresh alternatives. JP Morgan's Underweight rating suggests the stock offers limited upside even at current valuations.

General Mills' decision to divest Haagen-Dazs shops in China—a premium, higher-margin business—signals management is actively managing portfolio exposure amid demand uncertainty. However, a divestiture does not address the underlying category risk flagged by the analyst note.

Wall Street View

JP Morgan's $31 target is below General Mills' current trading price of $32.87, implying 5.7% downside. The Underweight rating joins broader sector caution on packaged food exposure to health trends. General Mills' trailing earnings growth of -14.5% (TTM) contrasts with its low valuation multiples, reflecting investor skepticism about near-term profit expansion.

Investor Takeaway

General Mills faces structural demand headwinds from GLP-1 adoption, and JP Morgan's target suggests limited near-term catalysts for stock appreciation. The Haagen-Dazs divestiture addresses margin pressure but does not resolve category-level demand concerns. Investors should assess their tolerance for exposure to secular food consumption trends before initiating positions.